Prellis Biologics is an organ and tissue engineering company using holographic bioprinting to revolutionize transplantation procedures. Immune rejection has made supplying organ transplants to demand a major challenge. Prellis’ approach involves their Externalized Immune System (EXISTM) platform that recreates human immunobiology in vitro in the form of lymph node organoids (LNOs). From LNOs, Prellis can advance drug discovery and development as they have direct access to a fully functional human immune system for antibody discovery, immunogenicity evaluation and vaccine development.

Prellis Biologics

Founded: 2016
Location: San Francisco, CA
Employee range: 11 - 50
Funding: $35M C Aug 2022; $14.5M B Dec 2021; $8.7M Jul 2019
Investors: Celesta Capital, Avidity Partners, Khosla Ventures, SOSV True Ventures, Lucas Venture Group

Short description:

Drug notes:

Long description:

Jobs: